Predictmedix Closes First Tranche of Private Placement
Predictmedix Closes First Tranche of Private Placement
TORONTO, ON / ACCESSWIRE / August 22, 2022 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED) (OTCQB:PMEDF), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), announces that it has closed the first tranche of a non-brokered private placement (the "First Tranche"). Pursuant to the First Tranche, the Company has issued 8,300,000 units (the "Units") at a price of $0.05 per unit to investors for gross proceeds of $415,000. Each Unit consists of one common share of the Company and one-half of one (1//2) common share purchase warrant (each whole warrant, a "Warrant"), whereby each Warrant entitles the holder to purchase one additional common share for a period of two years from closing at an exercise price of $0.10 per share. Net proceeds from the First Tranche will be used for general operations (working capital) including business development and technology upgrades. All securities issued in connection with the First Tranche are subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.
多伦多，on/ACCESSWIRE/2022/由专有人工智能(AI)支持的快速健康筛查解决方案的新兴提供商Predidicmedix Inc.(以下称PredicicMedix或公司)(CSE：PMED)(场外交易市场代码：PMEDF)宣布，它已经完成了非经纪私募的第一批(“第一批”)。根据第一批，公司以每单位0.05美元的价格向投资者发行了8,300,000个单位(“单位”)，总收益为415,000美元。每个单位包括一股本公司普通股和一份(1/2)普通股认购权证(每份完整认股权证，“认股权证”)的一半，据此，每份认股权证持有人有权在两年内以每股0.10美元的行使价购买一股额外的普通股。第一次付款的净收益将用于一般业务(营运资金)，包括业务发展和技术升级。所有与第一批相关发行的证券均受自证券发行之日起计四个月零一天的法定持有期的限制。
Accuracy Rates for Impairment and Infectious Diseases
损伤和传染病的准确率
The Company recently released its accuracy rates for identifying Respiration Rate, Heart Rate, and Core Body Temperature as part of its Fit for Duty screening solutions which together not only identify symptoms of infectious diseases but also parameters pertaining to fatigue detection. Additionally, the company announced accuracy rates for impairment detection in January. With the exceptional results from recent clinical trials, Predictmedix is advancing towards commercialization of its Fit for Duty screening solutions.
该公司最近发布了识别呼吸频率、心率和核心体温的准确率，作为其适合值班筛查解决方案的一部分，这些解决方案不仅可以识别传染病的症状，还可以识别与疲劳检测有关的参数。此外，该公司还在1月份公布了减损检测的准确率。凭借最近的临床试验取得的出色结果，Predidicmedix正在推进其Fit for Duty Screen解决方案的商业化进程。
Third-Party Validation of Technology's
技术的第三方验证
As part of the validation process of Predictmedix's Safe Entry technology, manuscripts are being prepared and finalized for submission for peer review. The process of peer review is expected to take up to 90 days, and upon completion of review, Predictmedix is expected to have its technology and recent studies validated so that the next phase of commercialization can ensue.
作为Predidicmedix安全进入技术验证过程的一部分，手稿正在准备和定稿，以供同行审查。同行审查过程预计需要长达90天的时间，审查完成后，Predidicmedix预计将对其技术和最近的研究进行验证，以便随后进行下一阶段的商业化。
Other Business Developments
其他业务发展
As the Company works to commercializing its Fit for Duty screening solutions, its resellers and partners are making significant progress in their advanced sales pipelines as well as forging partnerships with major Safety and Risk Management Corporations in North American along with several other jurisdictions.
随着公司努力将其Fit for Duty Screen解决方案商业化，其经销商和合作伙伴在其先进的销售渠道方面取得了重大进展，并与北美以及其他几个司法管辖区的主要安全和风险管理公司建立了伙伴关系。
The Company is set to debut and showcase Safe Entry's Fit for Duty to key industry executives in multiple upcoming conferences. Additionally, demo units are currently being sent to large potential clients and potential partners for scaling up Predictmedix's solutions in North America as well as international jurisdictions.
该公司将在即将举行的多个会议上首次亮相，并向主要行业高管展示Safe Entry适合值班的产品。此外，演示单元目前正被发送给大型潜在客户和潜在合作伙伴，以便在北美和国际司法管辖区扩大PredicicMedix的解决方案。
"The progress that we've made with the technology of our Fit for Duty screening solutions has propelled us into solving very important issues for corporations across many industries around the world. We believe Safe Entry's Fit for Duty can transform the way companies around the world maintains its people's productivity, wellness, health, and safety in an innovative and proven way. Lastly, we are thankful for all parties that have been involved in our success so far - our team, our partners, and our shareholders. As we commercialize Safe Entry's Fit for Duty screening solutions, we look forward to creating long-term value for our shareholders and we hope and encourage you continue to be a part of our story," commented Dr. Rahul Kushwah, Interim Chief Executive Officer at Predictmedix.
我们在我们的Fit for Duty Screen解决方案技术方面取得的进展推动我们为世界各地许多行业的公司解决了非常重要的问题。我们相信，Safe Entry‘s Fit to Duty可以改变世界各地的公司以一种创新和成熟的方式维护其员工的生产率、健康、健康和安全的方式。最后，我们感谢到目前为止参与我们成功的各方--我们的团队、我们的合作伙伴和我们的股东。随着Safe Entry适合值班筛查解决方案的商业化，我们期待着为我们的股东创造长期价值，我们希望并鼓励您继续成为我们故事的一部分。
About Predictmedix Inc.
关于Predicate Medix Inc.
Predictmedix (CSE:PMED) (OTCQB:PMEDF) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.
普瑞医疗(CSE：PMED)(场外市场代码：PMEDF)是一家新兴的全球快速健康筛查和远程患者护理解决方案提供商。该公司的安全入口站由专有人工智能(AI)提供支持，使用多光谱相机分析生理数据模式并预测各种健康问题，包括传染病(如新冠肺炎)、药物或酒精损害或各种精神疾病。PredidicMedix专有的远程患者护理平台为医疗专业人员提供了一套人工智能支持的工具，以改善患者的健康状况。要了解更多信息，请访问我们的网站，或在Twitter、Instagram或LinkedIn上关注我们。
Investor Relations Contact
投资者关系联系人
Corey Matthews
Investors@predictmedix.com
科里·马修斯
邮箱：Investors@forectmedix.com
Caution Regarding Forward-Looking Information:
有关前瞻性信息的警告：
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
本新闻稿可能包含基于当前预期的前瞻性陈述和信息。这些声明不应被解读为对公司未来业绩或结果的保证。这类陈述涉及已知和未知的风险、不确定因素和其他因素，可能导致实际结果、业绩或成就与这类陈述所暗示的大不相同。虽然这些陈述是基于管理层的合理假设，但不能保证这些假设将被证明是正确的。我们不承担更新或修改它们以反映新事件或新情况的责任。本公司的证券尚未根据修订后的《1933年美国证券法》(下称《美国证券法》)或适用的州证券法进行注册，除非进行注册或获得适用的豁免，否则不得向美国境内的人或美国人提供或出售，或为美国境内的人或“美国人”的账户或为他们的利益服务。本新闻稿不应构成出售要约或征求购买要约，也不应在美国或任何司法管辖区出售任何此类要约、征求或出售将是非法的证券。此外，存在已知和未知的风险因素，可能导致公司的实际结果、业绩或成就与本文中包含的前瞻性信息明示或暗示的未来结果、业绩或成就的第4页存在实质性差异，例如但不限于对获得监管部门批准的依赖；获得与其技术相关的知识产权的能力；有限的经营历史；一般商业、经济、竞争、政治、监管和社会方面的不确定性，尤其是, 与新冠肺炎有关的不确定性；与公司无法控制的因素有关的风险，包括与新冠肺炎有关的风险；与公司股票有关的风险，包括因可能或可能不在公司控制范围内的事件而引起的价格波动；对管理层的依赖；以及行业中更多竞争对手的紧急情况。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本文中的所有前瞻性信息都受本警示声明的约束，公司没有义务修改或更新任何此类前瞻性信息，也没有义务公开宣布对本文中包含的任何前瞻性信息的任何修改结果，以反映未来的结果、事件或发展，除非法律要求。
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."
免责声明：“本公司目前不会明示或暗示其产品有能力诊断、消除、治愈或控制新冠肺炎(或SARS-2冠状病毒)。”
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大证券交易所尚未对本新闻稿的充分性或准确性进行审查，也不承担任何责任。
SOURCE: PredictMedix Inc.
资料来源：PredidicMedex Inc.
译文内容由第三方软件翻译。